Sai Life Sciences Ltd

AGM Details

• 27th AGM scheduled for Thursday, September 17, 2026 at 10:30 A.M. IST via VC/OAVM.
• Cut-off date for voting: Thursday, September 10, 2026.
• Remote e-voting from 9:00 A.M. September 14, 2026 to 5:00 P.M. September 16, 2026.
• Annual report and AGM notice emailed to registered members.

Financial Performance

• Revenue for the quarter: INR553 crores; up about 12% YoY.
• CDMO 60%, CRO 40% revenue mix; CRO +26% YoY; CDMO +6%.
• Balance sheet remains healthy; financial flexibility to invest in opportunities.
• EcoVadis Platinum rating 2026; top 1% sustainability performers.
• Returning customers accounted for over 90% of revenue in FY25 and FY26.
• Calendar 2025: Sai contributed to five FDA-approved molecules; 17 launches in five years.

Business Model & Pipeline

• 65% of customers are served through integrated discovery-to-FTE model.
• Six late-phase molecules added in 15 months; five via large-pharma FTE engagements.
• Therapeutic distribution data available in investor deck (Slide 21).
• 19 of the top 25 pharma companies engaged with Sai Life Sciences.
• Four commercial contracts this year; three to be commercial supplies; two likely primary suppliers.
• Peptide development lab coming online; Hyderabad greenfield site peptide facility operational in 2028.

Capacity & Capex

• FY27 capex guidance INR 1,100 crores to INR 1,300 crores.
• FY28 capex guidance not provided yet.
• Discovery capacity online in Q1; Bidar blocks total 450 KL; first 225 KL block on stream.
• 1150 kilolitre capacity target by FY27.
• Greenfield peptide facility near Hyderabad operational in 2028; pilot-scale space being built.
• Peptide capex under INR 300 crores by end-FY2028.
• Boston and Manchester offshore facilities are stand-alone satellites; accretive to revenue.

Guidance & Outlook

• Long-term growth guidance: 15-20% revenue growth; EBITDA 28-30%.
• H2 FY27 expected to be stronger than H1 due to capacity ramp.

Meeting Details

• Date and time: 07 August 2026 at 04:00 PM IST.
• Type and mode: earnings call, virtual.
• Event/organiser: Sai Life Sciences Limited.
• Purpose: discuss un-audited Q1 FY27 results for quarter ended 30 June 2026.
• Recording: available on the company website.

Business Overview

• Integrated CRDMO with CRO and CDMO services from discovery to commercial manufacturing.
• Strategic focus on peptides, ADCs, oligos and AI-driven digitization.
• Listed on NSE/BSE; global footprint with facilities in Hyderabad, Bidar, Manchester, and Boston.

Operational Highlights

• Q1FY27 revenue ₹554 crore; YoY growth 12%; CRO grew 24%.
• 65% of customers receive integrated services; 33 active commercial and 14 late-phase CMC molecules.
• EcoVadis Platinum Rating 2026; top 1% sustainability.
• Capex largely on schedule; 100,000 sq ft R&D facility at Genome Valley, Hyderabad.
• Commercial-scale Photo Flow Chemistry for a late-phase program; enhances continuous processing.
• HTE platform commissioned at Hyderabad R&D campus for faster route scouting.
• New priorities ahead include integrated peptide platform and Drug Product facility.
• Capex investments support peptide platform and new Drug Product facility.
• Ground-breaking Process R&D block at Unit 2 Hyderabad doubling PRD capacity.
• New greenfield site in Choutuppal and expanded Unit IV Bidar capacity.

Financial Performance

• Revenue from operations ₹554 Cr in Q1FY27; total income ₹558 Cr.
• EBITDA ₹148 Cr; EBITDA margin 27%.
• Profit after tax ₹73 Cr; PAT margin ~13%.
• Q1FY27 expenses: materials ₹145 Cr; Employee benefits ₹180 Cr; Other ₹80 Cr; Forex gain ₹1 Cr.

Capital Structure & Liquidity

• Capex largely on schedule; balance sheet described as healthy.
• No debt or equity actions disclosed in this filing.

Strategic Priorities & Outlook

• Long-term growth guidance: revenue growth 15-20%; EBITDA 28-30%.
• Over 90% pipeline visibility for FY27; 65% integrated services.
• Aim to extend integrated offerings to large pharma collaborations.
• Capex includes integrated peptide platform and Drug Product facility.
• Ground break for PRD block and expansion at Hyderabad Bidar; Choutuppal land.

Risks & Mitigation

• Forward-looking statements carry risks; no explicit risk factors disclosed in this update.

Governance & Leadership

• CEO Krishna Kanumuri and CFO Siva Chittor provided commentary on momentum.
• Listed on NSE/BSE in 2024; 300+ employees; 19 of top 25 pharma customers.
• EcoVadis Platinum Rating 2026; PSCI membership; UN Global Compact signatory.
• Audited by USFDA, PMDA; strong regulatory track record.
• Regulatory excellence with USFDA/PMDA audits; 300+ QA/QC professionals.

Meeting Details

• Date and time: Friday, 07 August 2026, 04:00 PM IST.
• Type and mode: Earnings conference call, virtual (group) meeting.
• Event: Sai Life Sciences Q1FY27 Results Conference Call.
• Purpose: discuss unaudited quarterly results for quarter ended 30 June 2026; followed by interactive Q&A.

Participants

• Managing Director & Chief Executive Officer to present.
• Director and Chief Financial Officer to participate.

Additional Notes

• Pre-registration facility available for direct dial-in.

RTA certification

• Details of dematerialised/rematerialised securities during the period were furnished to all stock exchanges.